EP0495790A1 - Hybrid plasmids for the production of subtilisin carlsberg in bacillus - Google Patents

Hybrid plasmids for the production of subtilisin carlsberg in bacillus

Info

Publication number
EP0495790A1
EP0495790A1 EP19900912849 EP90912849A EP0495790A1 EP 0495790 A1 EP0495790 A1 EP 0495790A1 EP 19900912849 EP19900912849 EP 19900912849 EP 90912849 A EP90912849 A EP 90912849A EP 0495790 A1 EP0495790 A1 EP 0495790A1
Authority
EP
European Patent Office
Prior art keywords
protease
bacillus
plasmid
subtilisin carlsberg
plasmids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900912849
Other languages
German (de)
French (fr)
Inventor
Harald Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Publication of EP0495790A1 publication Critical patent/EP0495790A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus

Definitions

  • the invention relates to new hybrid plasmids which make it possible to express the alkaline protease subtilisin Carlsberg and related proteolytic enzymes in increased amounts in Bacillus.
  • proteases are known which are formed by microorganisms, in particular bacteria and fungi, and are removed from the cell by active transport, so that they collect in the culture medium. Numerous enzymes of this type are already being used industrially in processes that involve the degradation of proteins. Important applications are, for example, detergents and cleaning agents or also animal foods.
  • German patent application DE 35 27 913 describes hybrid plasmids for microorganisms of the genus Bacillus which contain a double-stranded DNA which has the following structure: promoter which is recognized by the RNA polymerase of microorganisms of the genus Bacillus, ribosome binding site , Start codon, structural gene which codes for subtilisin Carlsberg or its parts with proteolytic activity or variants with proteolytic activity including their leader sequences, stop codon.
  • German patent application P 38 21 491 describes that plasmids which produce an even higher protease expression can be obtained by dividing the piece of DNA which is in pC50 between two relatively adjacent Aval sites and a part of the promoter is removed by cutting with Aval and ligating.
  • the invention therefore relates to hybrid plasmids for generation. of protease in Bacillus, consisting of a Bacillus-common basic plasmid and a DNA sequence which codes for a protease of the Subti ⁇ lisin Carlsberg type, characterized in that a DNA sequence is inserted as protease sequence which is for a protease of the Subtilisin Carlsberg type is coded and upstream is limited by the Aval interface closest to the structure, downstream by the closest neighboring Sstl interface.
  • the cut between the SstI interface and the Aval interface closest to this interface is preferred in an output plasmid such as pC50.
  • a particularly preferred starting material is a plasmid pC50 according to DE 35 27 913.
  • the restriction endonuclease SstI cuts at base pair 1539 behind the protease gene or behind its transcriptional terminator.
  • the starting point is plasmids which contain the structural gene from Subtilisin Carlsberg or an enzyme similar to Subtilisin Carlsberg.
  • Subtilisin Carlsberg An enzyme similar to Subtilisin Carlsberg is understood here to mean those enzymes which differ from Subtilisin Carlsberg in up to 1% of the amino acids and which also have protease activity in a comparable manner. have their circumference, the structural genes having to have the interfaces mentioned.
  • the preferred starting material is a plasmid pC50, produced from a pBC16 portion and the structural gene of Subtilisin Carlsberg from Bacillus licheniformis DSM641 or from Bacillus licheniformis DSM 5440.
  • the corresponding starting plasmid is called pC50.
  • the Aval / SstI fragment from pC50 (FIG. 1) comprising subtilisin Carlsberg protease genes was cloned into the multiple cloning site of the E. coli vector pUC19 (1).
  • pC50 was cleaved with Aval and SstI and pUC19 ( Figure 2) with Xmal and SstI.
  • pC50 is additionally cleaved with PvuII, which leaves the Aval / SstI fragment carrying the protease gene part intact, but cuts the pBC16 vector part twice.
  • the enzymes were extracted twice with half the volume of phenol, based on the DNA solution, then mixed in a quantitative ratio of 1: 1, the mixture was extracted 5 times with the same volume of ether and then with twice the volume of ethanol 20 Incubated for minutes at -20 ° C and the DNA pelleted by centrifugation. After drying, the DNA was dissolved in a suitable buffer. The DNA concentration was adjusted to 20 ⁇ g / ml and T4 DNA ligase was added in a concentration of 1 U / ⁇ g of the DNA used. The ligase reaction was carried out at 6 ° C. for about 18 h.
  • the DNA was analyzed by the SDS-NaCl method by Guerry et al. (4), with subsequent cesium chloride density gradient centrifugation.
  • the bacillus vectors pUBUO (5; FIG. 4) and pBC16 (6; FIG. 5) were used as vectors for the cloning of the Aval / Sstl protease gene fragment. These two plasmids are largely homologous and differ essentially only in the resistance determinant (kanamycin for pUBUO and tetracycline for pBC16).
  • both pH9 and pUBUO and pBC16 were cleaved with BamHI and EcoRI, the latter being only incompletely EcoRI cleavage, since two EcoRI cleavage sites are present in pBC16, of which the cleavage site is in position 1 how the corresponding EcoRI site in pUBUO should be used for the insertion of the EcoRI / BamHI-P300 protease fragment.
  • BamHI and EcoRI sites in pH9 originate from the multiple cloning site of pUC19. Even in the case of pH9, the EcoRI cleavage must be carried out incompletely, since an additional EcoRI cleavage site exists in the protease gene.
  • pH9 to pUBUO or pBC16 in a quantitative ratio of 2: 1 was used for the ligation.
  • the total DNA concentration was 200 ⁇ g / ml.
  • the transformants were placed on full medium agar plates with 15 ⁇ g / ml tetracycline for ligation with pBC16 as vector, and 10 ⁇ g / ml Kanamycin selected for ligation with pUBUO as vector.
  • an immunological method was used which is based on a method by Broo e and Gilbert (8, 9). This method was already used in the original cloning of the subtilisin Carlsberg protease gene in the published patent application DE 3527 913 AI.
  • Immunologically positive clones were identified by means of restriction analysis of rapid lysates and the pBC16 derivative was designated as pC51 (FIG. 6) and the pUBHO derivative as pH70 (FIG. 7).
  • Bacillus subtilis SB202 pC51 and Bacillus subtilis SB202 pH70 were compared at 37 ° C to Bacillus subtilis SB202 in shake flasks in a complex medium suitable for protease production (9.1 g / 1 KH 2 P0, 11.8 g / 1 K 2 HP0 4 9/1 gS ⁇ 4x7H2 ⁇ , 0.5 g / 1 MnS ⁇ 4x2H 0, 0.2 g / 1 CaCl2 H2 ⁇ , 3 g / 1 soy flour, 18 g / 1 casein acc.
  • a complex medium suitable for protease production 9.1 g / 1 KH 2 P0, 11.8 g / 1 K 2 HP0 4 9/1 gS ⁇ 4x7H2 ⁇ , 0.5 g / 1 MnS ⁇ 4x2H 0, 0.2 g / 1 CaCl2 H2 ⁇ , 3 g / 1 soy flour, 18 g / 1 casein acc.
  • Bacillus subtilis SB202 1 Bacillus subtilis SB202 1
  • Bacillus subtilis SB202pH70 60-80
  • plasmid DNA was processed (10) and protoplasts from Bacillus licheniformis DSM5440 were hereby trans- formed.
  • the transformants were selected on DM3 agar (11) with 15 ⁇ g / ml tetracycline for the selection of pC51 and on mannitol agar (12) with 10 ⁇ g / ml neoycin for the selection of pH 70.
  • Colonies that were grown were inoculated onto calcium caseinate agar (Merck) with 15 ⁇ g / ml tetracycline (pC51) or 10 ⁇ g / ml kanamycin (pH70). Transformants which, after growth, had a lysis yard larger than E312 on these plates were checked for their agreement with the plasmid DNAs used for the transformation after restriction enzyme analysis of rapid lysates.
  • Example 3 Expression of pC51 / pH70 in Bacillus lichenifo ⁇ is DSM 5440
  • Bacillus liche ⁇ iformus DSM5440 which contains the plasmids pC50, pC51 or pH70, was shaken in a flask in a complex medium suitable for protease production (2.4 g / 1 H2PO, 1 g / 1 MgS ⁇ 4x7H2 ⁇ , 0.5 g / 1 MnS ⁇ 4x2H2 ⁇ , 0, 2 g / 1 CaCl2x2H 2 0.3 g / 1 soy flour, 12 g / 1 casein acc. To Hammarsten, 120 g / 1 amylase-treated potato starch) at 39 ° C and 34 ° C. Samples were taken at various times to determine protease activity.
  • a complex medium suitable for protease production 2.4 g / 1 H2PO, 1 g / 1 MgS ⁇ 4x7H2 ⁇ , 0.5 g / 1 MnS ⁇ 4x2H2 ⁇ , 0, 2 g / 1 CaCl2
  • protease measurements were carried out using N-CBZ-valine-p-nitrophenyl ester as the substrate, the substrate being cleaved into N-CBZ amino acid and p-nitrophenol * .
  • the formation of p-nitrophenol was measured as a measure of the activity of the protease at 340 nm in the photometer (13).
  • Strain Relative Protease Activity (%)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Lorsqu'on utilise des plasmides hybrides pour la production de protéase dans des bacilles, comprenant un plasmide de base caractéristique des bacilles et une séquence d'ADN réalisant le codage pour une protéase du type subtilisine Carlsberg, le pouvoir d'expression doit être accru. Ce résultat est obtenu grâce au fait qu'on utilise comme séquence de protéase le fragment d'ADN situé entre les interfaces AvaI et SstI les plus proches du gène structural de protéase et réalisant le codage pour la subtilisine Carlsberg.When hybrid plasmids are used for the production of protease in bacilli, comprising a basic plasmid characteristic of bacilli and a DNA sequence coding for a subtilisin Carlsberg type protease, the power of expression must be increased. This result is obtained by using the DNA fragment located between the AvaI and SstI interfaces closest to the protease structural gene and carrying out the coding for the subtilisin Carlsberg as protease sequence.

Description

"Hybridplasmide zur Erzeugung von Subtilisin Carlsberg in Bacillus" "Hybrid plasmids for the production of subtilisin Carlsberg in Bacillus"
Die Erfindung betrifft neue Hybridplasmide, die es ermöglichen, die alkalische Protease Subtilisin Carlsberg und damit verwandte pro- teolytische Enzyme in erhöhten Mengen in Bacillus zu exprimieren.The invention relates to new hybrid plasmids which make it possible to express the alkaline protease subtilisin Carlsberg and related proteolytic enzymes in increased amounts in Bacillus.
Es sind zahlreiche Proteasen bekannt, die von Mikroorganismen, ins¬ besondere Bakterien und Pilzen gebildet werden und durch aktiven Transport aus der Zelle ausgeschleust werden, so daß sie sich im Kulturmedium sammeln. Zahlreiche Enzyme dieser Art finden bereits technische Anwendung in Verfahren, bei denen es darum geht, Proteine abzubauen. Wichtige Anwendungen sind beispielsweise Wasch- und Rei¬ nigungsmittel oder auch Tiernahrungsmittel.Numerous proteases are known which are formed by microorganisms, in particular bacteria and fungi, and are removed from the cell by active transport, so that they collect in the culture medium. Numerous enzymes of this type are already being used industrially in processes that involve the degradation of proteins. Important applications are, for example, detergents and cleaning agents or also animal foods.
Aufgrund der technischen Bedeutung der Enzyme, die für die Protease Subtilisin Carlsberg etwas höher anzusetzen ist als für die Protease Subtilisin BPN1, hat es in der Vergangenheit bereits zahlreiche Ver¬ suche gegeben, Stämme aufzufinden, die das eine oder andere Enzym produzieren und die sich zur technischen Gewinnung der Produkte eignen. Verwiesen sei beispielsweise auf die folgenden deutschen Offenlegungs- oder Patentschriften: DE 1940488, DE 20 18451, DE 2044 161, DE 21 01 803, DE 21 21 397 und DE 29 25427 sowie auf GB 1 263 765, US 3 623 957, US 4264 738 und EP-A 6638. Bei den genannten Anmeldungen bzw. Patenten handelt es sich um klassische Mutationsverfahren, bei denen durch die häufige Wiederholung von Mutations- und Selektionsschritten letztendlich Produktionsstämme gewonnen werden, die im Hinblick auf Ausbeute oder Produktqualität optimiert sind. Es ist dem Fachmann bekannt, daß ein derartiger Mutationsprozeß statistisch abläuft, so daß kaum zu erwarten ist, daß dabei maßgeschneiderte Stämme entstehen, die das objektiv höchstmögliche Leistungsniveau aufweisen. Darüber hinaus können derartige Zuchtstämme auch zu Rückmutationen neigen, d.h. sie ver¬ lieren ihre günstigen Eigenschaften, zumindest teilweise und ver¬ wildern.Because of the technical importance of the enzymes, which is slightly higher for the protease subtilisin Carlsberg than for the protease subtilisin BPN 1 , there have been numerous attempts in the past to find strains which produce one or the other enzyme and which are suitable for the technical extraction of the products. For example, reference is made to the following German ones Laid-open or patent documents: DE 1940488, DE 20 18451, DE 2044 161, DE 21 01 803, DE 21 21 397 and DE 29 25427 as well as on GB 1 263 765, US 3 623 957, US 4264 738 and EP-A 6638. The applications and patents mentioned are classic mutation processes in which the repeated repetition of mutation and selection steps ultimately leads to production strains that are optimized with regard to yield or product quality. It is known to the person skilled in the art that such a mutation process takes place statistically, so that it is hardly to be expected that tailor-made strains are produced which have the objectively highest possible level of performance. In addition, breeding strains of this type can also tend to reverse mutations, ie they lose their favorable properties, at least in part and poach.
In der deutschen Offenlegungsschrift DE 35 27 913 werden Hybrid¬ plasmide für Mikroorganismen der Gattung Bacillus beschrieben, die eine doppelsträngige DNA enthalten, die den folgenden Aufbau auf¬ weist: Promotor, der von der RNA-Polymerase von Mikroorganismen der Gattung Bacillus erkannt wird, Ribosomenbindungsstelle, Startcodon, Strukturgen, das für Subtilisin Carlsberg oder dessen Teilstücke mit proteolytischer Aktivität oder Varianten mit proteolytischer Akti¬ vität einschließlich deren Leader-Sequenzen codiert, Stopcodon. Ein derartiges Konstrukt, bei dem die eingefügte DNA-Sequenz aus Bacil¬ lus licheniformis stammt und für Subtilisin Carlsberg kodiert und der restliche Plasmidteil von pBC16 stammt, wird Plasmid pC50 ge¬ nannt.German patent application DE 35 27 913 describes hybrid plasmids for microorganisms of the genus Bacillus which contain a double-stranded DNA which has the following structure: promoter which is recognized by the RNA polymerase of microorganisms of the genus Bacillus, ribosome binding site , Start codon, structural gene which codes for subtilisin Carlsberg or its parts with proteolytic activity or variants with proteolytic activity including their leader sequences, stop codon. Such a construct, in which the inserted DNA sequence originates from Bacillus licheniformis and codes for subtilisin Carlsberg and the remaining plasmid part originates from pBC16, is called plasmid pC50.
In der deutschen Patentanmeldung P 38 21 491 wird beschrieben, daß Plasmide, die eine noch höhere Protease-Expression bewirken, dadurch erhalten werden können, daß man das DNA-Stück, das in pC50 zwischen zwei relativ benachbarten Aval-Schnittstellen steht, und einen Teil des Promotors beinhaltet, durch Schneiden mit Aval und Ligieren entfernt.German patent application P 38 21 491 describes that plasmids which produce an even higher protease expression can be obtained by dividing the piece of DNA which is in pC50 between two relatively adjacent Aval sites and a part of the promoter is removed by cutting with Aval and ligating.
Vor dem Hintergrund dieses Standes der Technik ist es Aufgabe der Erfindung Plasmide zu liefern, die eine noch höhere Protease- Expression bewirken.Against the background of this prior art, it is the object of the invention to provide plasmids which bring about an even higher protease expression.
Gegenstand der Erfindung sind daher Hybridplasmide zur Erzeugung. von Protease in Bacillus, bestehend aus einem Bacillus-gängigen Grund- plasmid und einer DNA-Sequenz, die für eine Protease vom Typ Subti¬ lisin Carlsberg kodiert, dadurch gekennzeichnet, daß als Protease¬ sequenz eine DNA Sequenz eingefügt ist, die für eine Protease vom Typ Subtilisin Carlsberg kodiert und up-stream durch die dem Struk¬ turgen am nächsten benachbarte Aval-Schnittstelle, down-stream durch die am nächsten benachbarte Sstl-Schnittstelle begrenzt ist.The invention therefore relates to hybrid plasmids for generation. of protease in Bacillus, consisting of a Bacillus-common basic plasmid and a DNA sequence which codes for a protease of the Subti¬ lisin Carlsberg type, characterized in that a DNA sequence is inserted as protease sequence which is for a protease of the Subtilisin Carlsberg type is coded and upstream is limited by the Aval interface closest to the structure, downstream by the closest neighboring Sstl interface.
Bevorzugt ist jedenfalls das Schnittstück zwischen der Sstl-Schnitt¬ stelle und der dieser Schnittstelle am nächsten benachbarten Aval- Schnittstelle in einem Ausgangsplasmid wie pC50. Besonders bevor¬ zugtes Ausgangsmaterial ist ein Plasmid pC50 gemäß DE 35 27 913. Hier gilt, daß wenn die in Beziehung zur Leserichtung vor dem Pro- teasegen und ihm am nächsten liegende Aval-Schnittstelle am Basen¬ paar 1 schneidet, so schneidet die Restriktionsendonuclease SstI am Basenpaar 1539 hinter dem Proteasegen bzw. hinter seinem Traπscrip- tions-Terminator.In any case, the cut between the SstI interface and the Aval interface closest to this interface is preferred in an output plasmid such as pC50. A particularly preferred starting material is a plasmid pC50 according to DE 35 27 913. Here it applies that if the Aval interface which is closest in relation to the reading direction before the protease gene and at the base pair 1 cuts, the restriction endonuclease SstI cuts at base pair 1539 behind the protease gene or behind its transcriptional terminator.
Zur Erzeugung der erfindungsgemäßen Plasmide wird von Plasmiden ausgegangen, die das Strukturgeπ von Subtilisin Carlsberg oder einem Subtilisin Carlsberg ähnlichen Enzym enthalten.To generate the plasmids according to the invention, the starting point is plasmids which contain the structural gene from Subtilisin Carlsberg or an enzyme similar to Subtilisin Carlsberg.
Unter einem Subtilisin Carlsberg ähnlichen Enzym werden hier solche Enzyme verstanden, die in bis zu 1 % der Aminosäuren von Subtilisin Carlsberg abweichen und ebenfalls Proteaseaktivität im vergleichba- ren Umfang aufweisen, wobei die Strukturgene die genannten Schnitt¬ stellen aufweisen müssen.An enzyme similar to Subtilisin Carlsberg is understood here to mean those enzymes which differ from Subtilisin Carlsberg in up to 1% of the amino acids and which also have protease activity in a comparable manner. have their circumference, the structural genes having to have the interfaces mentioned.
Bevorzugtes Ausgangsmaterial ist ein Plasmid pC50, hergestellt aus einem pBC16-Anteil und dem Strukturgen von Subtilisin Carlsberg aus Bacillus licheniformis DSM641 oder aus Bacillus licheniformis DSM 5440. Das entsprechende Ausgangsplasmid trägt die Bezeichnung pC50.The preferred starting material is a plasmid pC50, produced from a pBC16 portion and the structural gene of Subtilisin Carlsberg from Bacillus licheniformis DSM641 or from Bacillus licheniformis DSM 5440. The corresponding starting plasmid is called pC50.
Um mehrere zusätzliche Restriktionsenzym-Spaltstellen für Umklo- nierungeπ zur Verfügung zu haben, wurde das Subtilisin Carlsberg- Proteasegen umfassende Aval/Sstl-Fragment aus pC50 (Figur 1) in die Multiple Cloning site des E. coli Vektors pUC19 (1) kloniert.In order to have several additional restriction enzyme cleavage sites available for recloning, the Aval / SstI fragment from pC50 (FIG. 1) comprising subtilisin Carlsberg protease genes was cloned into the multiple cloning site of the E. coli vector pUC19 (1).
Hierfür wurde pC50 mit Aval und SstI und pUC19 (Figur 2) mit Xmal und SstI gespalten. Um die Klonierung des Vektorteils aus pC50 in pUC19 zu verhindern, wird pC50 zusätzlich mit PvuII gespalten, das das den Proteasegenteil tragende Aval/Sstl-Fragment intakt läßt, aber den pBC16-Vektorteil 2mal schneidet. Nach der Inkubation wurden die Enzyme 2mal mit der halben Volumen Phenol, bezogen auf DNA-Lö¬ sung, extrahiert, dann im mengenmäßigen Verhältnis von 1 : 1 ge¬ mischt, das Gemisch 5mal mit gleichem Volumen Ether extrahiert und sodan mit doppeltem Volumen Ethanol 20 Minuten bei -20°C inkubiert und die DNA durch Zentrifugation pelletiert. Nach Trocknen wurde die DNA in geeignetem Puffer gelöst. Die DNA-Konzentration wurde auf 20 μg/ml eingestellt und T4-DNA-Ligase in einer Konzentration von 1 U/μg eingesetzter DNA zugegeben. Die Ligasereaktion wurde ca. 18 h bei 6°C durchgeführt.For this pC50 was cleaved with Aval and SstI and pUC19 (Figure 2) with Xmal and SstI. In order to prevent the cloning of the vector part from pC50 into pUC19, pC50 is additionally cleaved with PvuII, which leaves the Aval / SstI fragment carrying the protease gene part intact, but cuts the pBC16 vector part twice. After the incubation, the enzymes were extracted twice with half the volume of phenol, based on the DNA solution, then mixed in a quantitative ratio of 1: 1, the mixture was extracted 5 times with the same volume of ether and then with twice the volume of ethanol 20 Incubated for minutes at -20 ° C and the DNA pelleted by centrifugation. After drying, the DNA was dissolved in a suitable buffer. The DNA concentration was adjusted to 20 μg / ml and T4 DNA ligase was added in a concentration of 1 U / μg of the DNA used. The ligase reaction was carried out at 6 ° C. for about 18 h.
1 μg der mittels T4-DNA-Ligase verknüpften DNA-Fragmente wurden dann zur Transformation kompetenter Zellen (2) von Escherichia coli JM103 (3) benutzt. Selektioniert wurde auf LB-Mediu (Luria-Broth) mit 1% Agar mit 100 μg/ml Ampicillin. In Schnei1-Lysaten wurde durch Spaltung mit dem Restriktionsenzym PstI, das sowohl im Insert als auch im pUC19-Vektorteil im Multiple Cloning-Bereich spaltet, anhand des korrekten Spaltmusters der richtige Klon ausgewählt und als pH9 (Figur 3) bezeichnet.1 μg of the DNA fragments linked by means of T4 DNA ligase were then used to transform competent cells (2) from Escherichia coli JM103 (3). Selection was made on LB medium (Luria-Broth) with 1% agar with 100 μg / ml ampicillin. In Schnei1 lysates, the correct clone was selected on the basis of the correct cleavage pattern and designated as pH9 (FIG. 3) by cleavage with the restriction enzyme PstI, which cleaves in the insert and in the pUC19 vector part in the multiple cloning region.
Die DNA wurde nach der SDS-NaCl-Methode von Guerry et al. (4), mit nachfolgender Cäsiumchlorid-Dichtegradienten-Zentrifugation gewon¬ nen.The DNA was analyzed by the SDS-NaCl method by Guerry et al. (4), with subsequent cesium chloride density gradient centrifugation.
Als Vektoren für die Klonierung des Aval/Sstl-Proteasegenfragmeπts wurden die Bacillusvektoren pUBUO (5; Figur 4) und pBC16 (6; Figur 5) verwendet. Diese beiden Plasmide sind weitgehend homolog und un¬ terscheiden sich im wesentlichen nur in der Resistenz-Determinante (Kanamycin für pUBUO und Tetracyclin für pBC16). Zum Zwecke der Klonierung wurden sowohl pH9 als auch pUBUO und pBC16 mit BamHI und EcoRI gespalten, wobei bei letzterem die EcoRI-Spaltung nur unvoll¬ ständig erfolgen darf, da zwei EcoRI-Spaltstellen in pBC16 vorhanden sind, von denen die Spaltstelle in Pos. 1 wie die entsprechende EcoRI-Spaltstelle in pUBUO für die Insertion des EcoRI/BamHI-P300- Protease-Fragments genutzt werden soll. BamHI- und EcoRI-Spaltstel¬ len in pH9 stammen aus der Multiple Cloning site von pUC19. Auch im Falle des pH9 muß die EcoRI-Spaltung unvollständig vorgenommen wer¬ den, da eine zusätzliche EcoRI-Spaltstelle im Proteasegen existiert.The bacillus vectors pUBUO (5; FIG. 4) and pBC16 (6; FIG. 5) were used as vectors for the cloning of the Aval / Sstl protease gene fragment. These two plasmids are largely homologous and differ essentially only in the resistance determinant (kanamycin for pUBUO and tetracycline for pBC16). For the purpose of cloning, both pH9 and pUBUO and pBC16 were cleaved with BamHI and EcoRI, the latter being only incompletely EcoRI cleavage, since two EcoRI cleavage sites are present in pBC16, of which the cleavage site is in position 1 how the corresponding EcoRI site in pUBUO should be used for the insertion of the EcoRI / BamHI-P300 protease fragment. BamHI and EcoRI sites in pH9 originate from the multiple cloning site of pUC19. Even in the case of pH9, the EcoRI cleavage must be carried out incompletely, since an additional EcoRI cleavage site exists in the protease gene.
Für die Ligation wurde pH9 zu pUBUO bzw. pBC16 im mengenmäßigen Verhältnis 2 : 1 eingesetzt. Die Gesamt-DNA-Konzentration betrug 200 μg/ml.For the ligation, pH9 to pUBUO or pBC16 in a quantitative ratio of 2: 1 was used. The total DNA concentration was 200 μg / ml.
Die Transformation erfolgte in beiden Fällen in Bacillus subtilis SB202 (7).In both cases, the transformation was carried out in Bacillus subtilis SB202 (7).
Die Transformanten wurden auf Vollmediumagarplatten mit 15 μg/ml Tetracyclin für die Ligation mit pBC16 als Vektor, und 10 μg/ml Kanamycin für die Ligation mit pUBUO als Vektor, selektioniert. Für die Selektionierung Protease-produzierender Klone wurde eine immu¬ nologische Methode eingesetzt, die auf einem Verfahren von Broo e und Gilbert basiert (8, 9). Diese Methode wurde bereits bei der ursprünglichen Klonierung des Subtilisin Carlsberg Proteasegens in der Offenlegungsschrift DE 3527 913 AI angewandt.The transformants were placed on full medium agar plates with 15 μg / ml tetracycline for ligation with pBC16 as vector, and 10 μg / ml Kanamycin selected for ligation with pUBUO as vector. For the selection of protease-producing clones, an immunological method was used which is based on a method by Broo e and Gilbert (8, 9). This method was already used in the original cloning of the subtilisin Carlsberg protease gene in the published patent application DE 3527 913 AI.
Immunologisch positive Klone wurden mittels Restriktionsanalyse von Schnell-Lysaten identifiziert und der pBC16-Abkömmling als pC51 (Figur 6) sowie das pUBHO-Derivat als pH70 (Figur 7) bezeichnet. Immunologically positive clones were identified by means of restriction analysis of rapid lysates and the pBC16 derivative was designated as pC51 (FIG. 6) and the pUBHO derivative as pH70 (FIG. 7).
B e i s p i e l eB e i s p i e l e
Beispiel 1: Expression von Subtilisin Carlsberg Protease in Bacillus subtilisExample 1: Expression of subtilisin Carlsberg protease in Bacillus subtilis
Bacillus subtilis SB202 pC51 und Bacillus subtilis SB202 pH70 wurden bei 37°C vergleichend zu Bacillus subtilis SB202 in Schüttelkolben in einem für Proteaseproduktion geeigneten Komplexmedium (9,1 g/1 KH2P0 , 11,8 g/1 K2HP04. 1 9/1 gSθ4x7H2θ, 0,5 g/1 MnSθ4x2H 0, 0,2 g/1 CaCl2 H2θ, 3 g/1 Sojamehl, 18 g/1 Casein nach Hammarsten,Bacillus subtilis SB202 pC51 and Bacillus subtilis SB202 pH70 were compared at 37 ° C to Bacillus subtilis SB202 in shake flasks in a complex medium suitable for protease production (9.1 g / 1 KH 2 P0, 11.8 g / 1 K 2 HP0 4 9/1 gSθ4x7H2θ, 0.5 g / 1 MnSθ4x2H 0, 0.2 g / 1 CaCl2 H2θ, 3 g / 1 soy flour, 18 g / 1 casein acc. To Hammarsten,
180 g/1 Amylase-behandelte Kartoffelstärke) angezogen. Zu verschie¬ denen Zeitpunkten wurden Proben zur Bestimmung der Proteaseaktivität genommen. Die Proteaseaktivität wurde mittels Cenco-Autoanalysator (Firma Skalar) gemessen. Dabei wird die enzymhaltige Lösung mit dem Substrat Dimethylcasein inkubiert. Es entstehen durch Proteolyse primäre Aminogruppen, die unter Bildung eines stabilen gelben Kom¬ plexes mit 2,4,6-Trinitrobenzolsulfonsäure reagieren. Die Farbmes¬ sung erfolgt im kontinuierlichen Durchfluß bei 420 nm.180 g / 1 amylase-treated potato starch). Samples were taken at various times to determine the protease activity. The protease activity was measured using a Cenco auto analyzer (company Skalar). The enzyme-containing solution is incubated with the substrate dimethyl casein. Proteolysis produces primary amino groups which react with 2,4,6-trinitrobenzenesulfonic acid to form a stable yellow complex. The color measurement takes place in a continuous flow at 420 nm.
Stamm relative ProteaseaktivitätStrain relative protease activity
Bacillus subtilis SB202 1Bacillus subtilis SB202 1
Bacillus subtilis SB202pC51 ca. 2Bacillus subtilis SB202pC51 ca.2
Bacillus subtilis SB202pH70 (DSM 5479) 60-80Bacillus subtilis SB202pH70 (DSM 5479) 60-80
Beispiel 2: Transformation von Bacillus licheniformis DSM 5440Example 2: Transformation of Bacillus licheniformis DSM 5440
Von den Stämmen Bacillus subtilis SB202pC51 und Bacillus subtilis SB202pH70 (DSM 5479) wurde Plasmid-DNA aufgearbeitet (10) und Protoplasten von Bacillus licheniformis DSM5440 hiermit trans- formiert. Die Transformanten wurden auf DM3-Agar (11) mit 15 μg/ml Tetracyclin für die Selektionierung von pC51 und auf Mannitol-Agar (12) mit 10 μg/ml Neo ycin für die Selektionierung von pH 70 selek¬ tioniert.From the strains Bacillus subtilis SB202pC51 and Bacillus subtilis SB202pH70 (DSM 5479), plasmid DNA was processed (10) and protoplasts from Bacillus licheniformis DSM5440 were hereby trans- formed. The transformants were selected on DM3 agar (11) with 15 μg / ml tetracycline for the selection of pC51 and on mannitol agar (12) with 10 μg / ml neoycin for the selection of pH 70.
Gewachsene Kolonien wurden auf Calcium-Caseinat-Agar (Merck) mit 15 μg/ml Tetracyclin (pC51) bzw. 10 μg/ml Kanamycin (pH70) über¬ impft. Transformanten, die nach Wachstum einen gegenüber E312 grö¬ ßeren Lysehof auf diesen Platten aufwiesen, wurden nach Restrikti¬ onsenzymanalyse von Schnell-Lysaten auf ihre Übereinstimmung mit den für die Transformation verwendeten Plasmid-DNAs überprüft.Colonies that were grown were inoculated onto calcium caseinate agar (Merck) with 15 μg / ml tetracycline (pC51) or 10 μg / ml kanamycin (pH70). Transformants which, after growth, had a lysis yard larger than E312 on these plates were checked for their agreement with the plasmid DNAs used for the transformation after restriction enzyme analysis of rapid lysates.
Beispiel 3: Expression von pC51/pH70 in Bacillus lichenifoππis DSM 5440Example 3: Expression of pC51 / pH70 in Bacillus lichenifoππis DSM 5440
Bacillus licheπiformus DSM5440, der die Plasmide pC50, pC51 oder pH70 enthält, wurde in Schüttelkolben in einem für Proteaseproduk- tion geeigneten Komplexmedium (2,4 g/1 H2PO , 1 g/1 MgSθ4x7H2θ, 0,5 g/1 MnSθ4x2H2θ, 0,2 g/1 CaCl2x2H20, 3 g/1 Sojamehl, 12 g/1 Casein nach Hammarsten, 120- g/1 Amylase-behandelte Kartoffelstärke) bei 39°C und 34°C angezogen. Zu verschiedenen Zeitpunkten wurden Proben zur Bestimmung der Proteaseaktivität genommen. Die Protease- messungen wurden mit N-CBZ-valin-p-nitrophenylester als Substrat durchgeführt, wobei das Substrat in N-CBZ-Aminosäure und p-Nitro- phenol gespalten wird*. Die Bildung des p-Nitrophenols wurde als Maß für die Aktivität der .Protease bei 340 nm im Photometer gemessen (13). Stamm Relative Proteaseaktivität ( % )Bacillus licheπiformus DSM5440, which contains the plasmids pC50, pC51 or pH70, was shaken in a flask in a complex medium suitable for protease production (2.4 g / 1 H2PO, 1 g / 1 MgSθ4x7H2θ, 0.5 g / 1 MnSθ4x2H2θ, 0, 2 g / 1 CaCl2x2H 2 0.3 g / 1 soy flour, 12 g / 1 casein acc. To Hammarsten, 120 g / 1 amylase-treated potato starch) at 39 ° C and 34 ° C. Samples were taken at various times to determine protease activity. The protease measurements were carried out using N-CBZ-valine-p-nitrophenyl ester as the substrate, the substrate being cleaved into N-CBZ amino acid and p-nitrophenol * . The formation of p-nitrophenol was measured as a measure of the activity of the protease at 340 nm in the photometer (13). Strain Relative Protease Activity (%)
39°C 34°C39 ° C 34 ° C
DSM 5440 mit pC50 80 - 100 % 120 - 130 %DSM 5440 with pC50 80 - 100% 120 - 130%
DSM 5440 mit pC51 130 % 160 % Hiπterlegungsnummer DSM 5478DSM 5440 with pC51 130% 160% accession number DSM 5478
DSM 5440 mit pH70 100 - 120 % 135 %DSM 5440 with pH70 100 - 120% 135%
* Die Angaben beziehen sich auf DSM 5440 bei 39°C.* The data refer to DSM 5440 at 39 ° C.
Bei 34°C kommt es unter den angegebenen Bedingungen offensichtlich zu einer besseren Proteaseausbeute mit den rekombinanten Plasmiden pC50, pC51 und pH70; was vermutlich auf die bessere SauerstoffVer¬ sorgung der Stämme bei gleichzeitig langsamerem Wachstum und höherer Stabilität der Plasmide zurückzuführen ist.At 34 ° C there is obviously a better protease yield with the recombinant plasmids pC50, pC51 and pH70; which is presumably due to the better oxygen supply to the strains with slower growth and greater stability of the plasmids.
MethodenMethods
Wenn im Text nicht andere Angaben gemacht wurden, wurde insbesondere für folgende Methoden das Handbuch von Maniatis, T. , Fritsch, E.F. &Unless otherwise stated in the text, the manual by Maniatis, T., Fritsch, E.F. &
Sambrook, J., Molecular Cloning, A Laboratory Manual (1982) zugrun¬ degelegt:Sambrook, J., Molecular Cloning, A Laboratory Manual (1982):
* Phenolisierung von DNA* Phenolization of DNA
* Ethanolfällung von DNA* DNA ethanol precipitation
* Ligation von DNA Literatur* Ligation of DNA literature
1. Yanisch-Perron, C, Vieira, J. & Messing, J., Gene 33: 103 (1985)1. Yanisch-Perron, C, Vieira, J. & Messing, J., Gene 33: 103 (1985)
Kornmerziell erhältlich durch z.B. Biolabs New EnglandCommercially available through e.g. Biolabs New England
2. Mandel, M. & Higa, A., J. Mol. Biol. 53: 154 (1970)2. Mandel, M. & Higa, A., J. Mol. Biol. 53: 154 (1970)
3. Messing, J., Crea, J.R. & Seeburg, P.H., Nucleic Acids Res. 9: 309 (1981)3. Messing, J., Crea, J.R. & Seeburg, P.H., Nucleic Acids Res. 9: 309 (1981)
4. Guerry, P., LeBlanc, D.J. & Falkow, S., J. Bacteriol. 116: 1064 (1973)4. Guerry, P., LeBlanc, D.J. & Falkow, S., J. Bacteriol. 116: 1064 (1973)
5. Bacillus Genetic Stock Center Nr. 1E65. Bacillus Genetic Stock Center No. 1E6
6. Bacillus Genetic Stock Center Nr. 1E9 / DSM 4026. Bacillus Genetic Stock Center No. 1E9 / DSM 402
7. Copeland, J.C. Marmur, J. Bacteriol. Rev. 32. : 302 - 312 (1968)7. Copeland, J.C. Marmur, J. Bacteriol. Rev. 32: 302-312 (1968)
8. Broome, S. & Gilbert, W., Proc. Natl. Acad. Sc. U.S.A. 75: 2746 (1978)8. Broome, S. & Gilbert, W., Proc. Natl. Acad. Sc. U.S.A. 75: 2746 (1978)
9. Buckel, P. & Zehelein, E.f Gene 16: 149 (1981)9. Buckel, P. & Zehelein, E. f Gene 16: 149 (1981)
10. Godson, G.N. & Vapnek, D., Biochim. Biophys. Acta 299: 516 (1973)10. Godson, G.N. & Vapnek, D., Biochim. Biophys. Acta 299: 516 (1973)
11. Chang, S. & Cohen, S.N., Molec. Gen. Genet. 168: 111 (1979)11. Chang, S. & Cohen, S.N., Molec. Gene. Genet. 168: 111 (1979)
12. Bourne, N., Dancer, B.N., J. Gen. Microbio. 132: 251 (1986)12. Bourne, N., Dancer, B.N., J. Gen. Microbio. 132: 251 (1986)
13 Dupaix, A., Bechet, J.-J. & Roncons, C, Biochem. Biophys. Res. Commun. 41: 464 (1979) 13 Dupaix, A., Bechet, J.-J. & Roncons, C, Biochem. Biophys. Res. Commun. 41: 464 (1979)

Claims

P a t e n t a n s p r ü c h e Patent claims
1. Hybridplasmide zur Erzeugung von Protease in Bacillus, bestehend aus einem Bacillus-gängigen Grundplasmid und einer DNA-Sequenz, die für eine Protease vom Typ Subtilisin Carlsberg kodiert, da¬ durch gekennzeichnet, daß als Protease-Sequeπz eine DNA Sequenz eingefügt ist, die für eine Protease vom Typ Subtilisin Carls¬ berg kodiert und up-stream durch die dem Strukturgen am nächsten benachbarte Aval-Schnittstelle, down-stream durch die am näch¬ sten benachbarte Sstl-Schnittstelle begrenzt ist.1. Hybrid plasmids for the production of protease in Bacillus, consisting of a Bacillus-common basic plasmid and a DNA sequence which codes for a protease of the subtilisin Carlsberg type, characterized in that a DNA sequence is inserted as the protease sequence encoded for a protease of the Subtilisin Carls¬ berg type and upstream is limited by the Aval interface closest to the structural gene, downstream by the closest neighboring SstI interface.
2. Hybridplamid nach Anspruch 1, dadurch gekennzeichnet, daß als Grundplasmid das Bacillus-Plasmid pBC 16 enthalten ist (Plasmid pC51).2. Hybrid plamide according to claim 1, characterized in that the basic plasmid is the Bacillus plasmid pBC 16 (plasmid pC51).
3. Hybridplasmid nach Anspruch 1, dadurch gekennzeichnet, daß als Grundplasmid das Bacillus-Plasmid pUBUO enthalten ist (Plasmid pH70).3. Hybrid plasmid according to claim 1, characterized in that the basic plasmid is the Bacillus plasmid pUBUO (plasmid pH70).
4. Transformierte. Stämme der Gattung Bacillus subtilis und/oder licheniformis enthalten Plasmide nach den Ansprüchen 1 bis 3.4. Transformed . Strains of the genus Bacillus subtilis and / or licheniformis contain plasmids according to claims 1 to 3.
5. Transformierte Stämme Bacillus subtilis SB202 pH 70 (DSM 5479) und Bacillus licheniformis pC 51 (DSM 5478). 5. Transformed strains Bacillus subtilis SB202 pH 70 (DSM 5479) and Bacillus licheniformis pC 51 (DSM 5478).
EP19900912849 1989-08-25 1990-08-16 Hybrid plasmids for the production of subtilisin carlsberg in bacillus Withdrawn EP0495790A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3928046 1989-08-25
DE19893928046 DE3928046A1 (en) 1989-08-25 1989-08-25 HYBRID PLASMIDE FOR THE PRODUCTION OF SUBTILISIN CARLSBERG IN BACILLUS

Publications (1)

Publication Number Publication Date
EP0495790A1 true EP0495790A1 (en) 1992-07-29

Family

ID=6387817

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900912849 Withdrawn EP0495790A1 (en) 1989-08-25 1990-08-16 Hybrid plasmids for the production of subtilisin carlsberg in bacillus

Country Status (3)

Country Link
EP (1) EP0495790A1 (en)
DE (1) DE3928046A1 (en)
WO (1) WO1991002802A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3527913A1 (en) * 1985-08-03 1987-02-12 Henkel Kgaa ALKALINE PROTEASE, METHOD FOR PRODUCING HYBRID VECTORS AND GENETICALLY TRANSFORMED MICROORGANISMS
DE3821491A1 (en) * 1988-06-25 1989-12-28 Henkel Kgaa HYBRID PLASMIDE FOR THE PRODUCTION OF SUBTILISIN CARLSBERG IN BACILLUS
DE3824827A1 (en) * 1988-07-21 1990-02-01 Henkel Kgaa PLASMIDES FOR GENERATING ALPHA AMYLASE IN BACILLUS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9102802A1 *

Also Published As

Publication number Publication date
WO1991002802A1 (en) 1991-03-07
DE3928046A1 (en) 1991-02-28

Similar Documents

Publication Publication Date Title
DE69034195T2 (en) subtilisin mutants
EP0481008B1 (en) Process for preparing a protein by a fungus transformed by multicopy integration of an expression vector
KR0181179B1 (en) Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising the same
EP0415296B2 (en) High alkaline proteases
AU643511B2 (en) Bacterial vectors
DE69535704T2 (en) EXPRESSION PLASMIDE, REGULATED BY AN osmB PROMOTER
DE69723855T2 (en) METHOD FOR PRODUCING POLYPEPTIDES IN SURFACTIN MUTANTS OF BACILLUS CELLS
JPH01502398A (en) Stable gene amplification in chromosomal DNA of prokaryotic microorganisms
EP1360283B1 (en) Expression of recombinant proteinase k from tritirachium album in yeast
DE69333249T2 (en) New mold protease
CA1313152C (en) Enhancing dna sequences
DE4020438A1 (en) New plasmids for expressing urine plasminogen activator
EP0388593A1 (en) Method for the expression of polygalacturonidase and pectinesterase in Aspergillus niger and Aspergillus awamori
US5015574A (en) DNA sequence involved in gene expression and protein secretion, expression-secretion vector including the DNA sequence and the method of producing proteins by using the expression-secretion vector
EP0495790A1 (en) Hybrid plasmids for the production of subtilisin carlsberg in bacillus
DD297187A5 (en) EFFECTIVE MANUFACTURE OF MUTANT PROTEASES
DE69334143T2 (en) CHANGED KLUYVEROMYCES YEAST THEIR MANUFACTURE AND USE
GB2171703A (en) Expression-secretion vector
DE69928830T2 (en) PROTEIN PRODUCTION IN GRAM-POSITIVE MICRO-ORGANISMS
EP0348814B1 (en) Hybrid plasmid for producing subtilisin Carlsberg in bacillus
HU197351B (en) Process for preparing polypeptide from genetically codeable aminoacids
DE69333564T2 (en) nisins
EP0662126A1 (en) Mutated subtilisine-like serin proteases
WO1991002064A2 (en) Modified proteases and their use in foodstuffs
EP0610808A2 (en) Improved high alkaline proteases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

D17P Request for examination filed (deleted)
R17P Request for examination filed (corrected)

Effective date: 19920523

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19930504